Efficacy of Treatment Sequences in Patients With Non-small Cell Lung Cancer Receiving Lorlatinib

CompletedOBSERVATIONAL
Enrollment

291

Participants

Timeline

Start Date

February 1, 2019

Primary Completion Date

October 12, 2020

Study Completion Date

October 12, 2020

Conditions
Non-small Cell Lung Cancer MetastaticALK Gene Rearrangement PositiveROS-1 Gene Rearrangement Positive
Trial Locations (30)

Unknown

Aix-en-Provence - CH, Aix-en-Provence

Angers - CHU, Angers

Annemasse - CH, Annemasse

Avignon - CH, Avignon

Bordeaux - Polyclinique, Bordeaux

Brest - Morvan CHU, Brest

Cahors - CH, Cahors

Chartres-CH, Chartres

Clermont-Ferrand - CHU, Clermont-Ferrand

Colmar - CH, Colmar

Créteil - CHI, Créteil

La Roche-Sur-Yon - CH, La Roche-sur-Yon

Libourne - CH, Libourne

Lorient - CHBS, Lorient

Lyon - CRLCC, Lyon

Marseille - CRLCC, Marseille

Montpellier - ICM, Montpellier

Mulhouse - GHRMSA, Mulhouse

Paris - Curie, Paris

Paris - Saint-Louis, Paris

Paris - Tenon, Paris

Lyon - URCOT, Pierre-Bénite

Reims - CHU, Reims

Saint-Etienne - CHU, Saint-Etienne

Saint-Nazaire - Clinique Mutualiste de l'Estuaire, Saint-Nazaire

Toulouse - CHU, Toulouse

Tours - CHU, Tours

Valenciennes - Clinique, Valenciennes

Vandoeuvre-lès-Nancy - CRLCC, Vandœuvre-lès-Nancy

Villejuif - Gustave Roussy, Villejuif

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Intergroupe Francophone de Cancerologie Thoracique

OTHER

NCT03727477 - Efficacy of Treatment Sequences in Patients With Non-small Cell Lung Cancer Receiving Lorlatinib | Biotech Hunter | Biotech Hunter